{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:01:58Z","timestamp":1781078518924,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.msard.2025.106846","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T15:58:01Z","timestamp":1762617481000},"page":"106846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploring the wearing-off phenomenon among anti-CD20 therapies in multiple sclerosis"],"prefix":"10.1016","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2975-9323","authenticated-orcid":false,"given":"Andr\u00e9 Aires","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mafalda","family":"Seabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Mendon\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Soares dos Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106846_bib0019","first-page":"458","article-title":"Natalizumab extended interval dosing: what about wearing-off effect?","author":"Bernardes","year":"2024","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106846_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102020","article-title":"End of dose interval symptoms in patients treated with natalizumab: a role for serum cytokines?","volume":"41","author":"Cath\u00e9rine","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2025.106846_bib0014","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000706","article-title":"Natalizumab wearing-off effect: the hunt for the elusive pharmacodynamic biomarker","volume":"7","author":"Foley","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.msard.2025.106846_bib0005","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2025.106846_bib0007","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2025.106846_bib0008","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2025.106846_bib0006","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann. Neurol."},{"issue":"10422","key":"10.1016\/j.msard.2025.106846_bib0003","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","article-title":"Multiple sclerosis","volume":"403","author":"Jakimovski","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2025.106846_bib0013","article-title":"Wearing-off phenomenon in multiple sclerosis patients on ofatumumab: a case series","volume":"3","author":"Labani","year":"2023","journal-title":"Neuroimmunol. Rep."},{"issue":"2","key":"10.1016\/j.msard.2025.106846_bib0012","article-title":"The patient-reported wearing-off phenomenon with monoclonal antibody treatments for multiple sclerosis","volume":"10","author":"Marian","year":"2024","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"8","key":"10.1016\/j.msard.2025.106846_bib0002","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMa"},{"issue":"8","key":"10.1016\/j.msard.2025.106846_bib0017","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1007\/s00415-024-12434-w","article-title":"The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis","volume":"271","author":"Monteiro","year":"2024","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106846_bib0001","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2025.106846_bib0004","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jbspin.2009.03.010","article-title":"Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects","volume":"76","author":"Renaudineau","year":"2009","journal-title":"Joint. Bone Spine"},{"issue":"3","key":"10.1016\/j.msard.2025.106846_bib0016","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s004210050679","article-title":"Body surface area: du Bois and Du Bois revisited","volume":"82","author":"Shuter","year":"2000","journal-title":"Eur. J. Appl. Physiol."},{"issue":"8","key":"10.1016\/j.msard.2025.106846_bib0009","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus Teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106846_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103364","article-title":"The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis","volume":"57","author":"Toorop","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"13","key":"10.1016\/j.msard.2025.106846_bib0018","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1177\/13524585241293940","article-title":"Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients","volume":"30","author":"Toorop","year":"2024","journal-title":"Mult. Scler."},{"issue":"17","key":"10.1016\/j.msard.2025.106846_bib0011","doi-asserted-by":"crossref","first-page":"e1579","DOI":"10.1212\/WNL.0000000000008357","article-title":"The natalizumab wearing-off effect: end of natalizumab cycle, recurrence of MS symptoms","volume":"93","author":"van Kempen","year":"2019","journal-title":"Neurology."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:31:42Z","timestamp":1781076702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825005887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":19,"alternative-id":["S2211034825005887"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106846","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the wearing-off phenomenon among anti-CD20 therapies in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106846","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106846"}}